Lexaria Bioscience Corp. LXRP Archives

WednesdayJun 24, 2020 10:08 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Announces Results from 2020 Annual and Special Meeting

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), a global innovator in drug delivery platforms, today announced the results of the 2020 Annual and Special Meeting (the "Meeting"). According to the update, the Meeting was held at 1:00 p.m. (Pacific Time) on June 23, 2020, whereby there were 47,819,789 shares of the Company represented in person or by proxy, constituting 53.38% of the Company's issued share capital as at May 13, 2020, being the record date of the Meeting. All of the proposals are described in detail in the Company's proxy statement filed with the Securities Exchange Commission via Edgar and…

ThursdayJun 18, 2020 10:28 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Applies for NIH Grant to Support COVID-19 Therapy Studies, Receives Expanded Health Canada License

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), a global innovator in drug delivery platforms, today announced its submission of a grant application to the U.S. National Institutes of Health (“NIH”) entitled "In vitro and in vivo animal exploratory pharmacokinetic and preliminary efficacy modelling of select orally administered antiviral compounds following DehydraTECH formulation enhancement." According to the update, the grant application is for funding to support Lexaria's second round of planned studies related to COVID-19 treatment possibilities. Additionally, the Company also reported that its subsidiary Lexaria CanPharm ULC has received a new license from Health Canada, issued in accordance with the…

TuesdayJun 02, 2020 9:59 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Engages PCG of New York for IR and Digital Marketing Services

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), a global innovator in drug delivery platforms, on Monday announced that it has retained PCG Advisory, Inc. ("PCG") of New York, to provide investor relations and digital marketing services to the Company in compliance with regulatory guidelines. According to the update, PCG's sectors of deepest experience include life sciences, technology and cannabis, and it reaches thousands of individual, retail and institutional investors daily using the latest social media and digital marketing techniques. PCG will develop a comprehensive strategy to increase investor awareness of Lexaria, amplify market visibility, and introduce the Company to its…

TuesdayMay 12, 2020 9:35 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Closes Private Placement

Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), a global innovator in drug delivery platforms, on Monday announced the close of its private placement financing. The company issued a total amount of 8,028,254 shares of its common stock along with common stock purchase warrants to purchase up to 8,028,254 shares of its common stock for gross proceeds of US$1,846,498 in its first tranche which closed on May 6, 2020. Lexaria closed the second tranche of its private placement on May 11, 2020 for the further issuance of 837,957 shares along with 837,957 warrants for gross proceeds of US$192,730. The warrants are immediately…

MondayMay 04, 2020 10:43 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Announces Over US$2 Million Private Placement

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), a global innovator in drug delivery platforms, today announced its entry into definitive agreements with certain qualified investors for the sale of 8,978,260 shares ("Shares") of its common stock along with common stock purchase warrants ("Warrants") to purchase up to 8,978,260 shares of its common stock in a private placement (collectively the "Offering") for gross proceeds of over US$2 million. According to the update, the purchase price per Share is US$0.23. The Warrants being issued in connection with the purchase of the Shares are immediately exercisable at an exercise term of five years…

ThursdayApr 23, 2020 10:10 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Announces Notice of Allowance for New Patent, Issuance of Stock Options Under Equity Incentive Plan

Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), a global innovator in drug delivery platforms, today announced its receipt of a Notice of Allowance from the United States Patent and Trademark Office ("USPTO") for a new patent. According to the update, the new patent provides additional claims that protect the use of its DehydraTECH(TM) technology together with cannabinoids, nicotine, nonsteroidal anti-inflammatory drugs, or vitamins in mix and serve beverage formats. This patent, with application number 16/497,920 under the title "Food and Beverage Compositions Infused With Lipophilic Active Agents and Methods of Use Thereof," signifies another addition to Lexaria's first patent family, under…

TuesdayApr 21, 2020 9:46 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Files New Patent Application for DehydraTECH Technology in Delivery of Antiviral Drugs

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), a global innovator in drug delivery platforms, today announced that it has filed an important new patent application in the United States describing the use of its DehydraTECH(TM) technology for the delivery of antiviral drugs. According to the update, the technology would potentially be used to improve treatment options for viral infectious diseases including COVID-19, MERS, SARS, influenza, herpes, hepatitis and AIDS. "Lexaria's proprietary drug delivery platform has already proven its effectiveness in the oral delivery of other lipophilic drugs such as nicotine, cannabinoids, and more, with multi-fold increases in both the rate…

WednesdayMar 25, 2020 9:58 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) to Webcast Live at March 26 Life Sciences Investor Forum

Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), a global innovator in drug delivery platforms, on Tuesday announced that its Chief Executive Officer, Chris Bunka, will present live at LifeSciencesInvestorForum.com on March 26. According to the update, Bunka’s presentation is scheduled to begin at 12:00 PM ET. The live, interactive online event invites investors to ask the company questions in real-time. It is suggested that interested parties pre-register and run the online system check to expedite participation and receive event updates. An archived webcast will be made available after the event for those unable to join live on the day of the…

TuesdayMar 24, 2020 10:06 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) to Participate in Life Sciences Investor Forum’s Virtual Conference

Life Sciences Investor Forum today announced the schedule for its inaugural event for both public and private companies, investors and worldwide industry professionals. The one-day event is kicking off on Thursday, March 26 with the first live webcast at 9:30 AM ET. Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), a global innovator in drug delivery platforms, is scheduled to provide a presentation at 12:00 PM ET on March 26. Per the release, pre-registration is recommended for investors and it is encouraged that they run the online system check to expedite participation and receive event updates. There is no cost to view…

MondayMar 23, 2020 11:51 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Announces Expansion of Pharmaceutical Division to Include Lipophilic Antiviral Active Molecules for COVID-19 Treatment

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), a global innovator in drug delivery platforms, today announced expansion of the scope and activities of its 100%-owned subsidiary Lexaria Pharmaceutical Corp. According to the update, Lexaria Pharmaceutical will investigate how the company’s patented DehydraTECH(TM) drug delivery technology could enhance delivery and effectiveness of certain antiviral drugs in the fight against coronavirus disease COVID-19. Lexaria intends to expand collaboration with leading laboratories across North America and internationally as soon as possible. To view the full press release, visit http://ibn.fm/5ILIz About Lexaria Lexaria Bioscience Corp. is a global innovator in drug delivery platforms. Its…

Site Search

Company Search

Tag: Lexaria Bioscience Corp. LXRP